INTELLIA THERAPEUTICS

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022

06 1 2022 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

05 1 2022 15:01:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases

05 1 2022 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer

20 12 2021 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

13 12 2021 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

22 11 2021 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting

05 11 2021 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

04 11 2021 06:30:01 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates

28 10 2021 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

21 10 2021 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress

20 10 2021 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

13 10 2021 06:01:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

06 10 2021 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference

27 9 2021 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia

16 9 2021 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Present at September Healthcare Investor Conferences

31 8 2021 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

05 8 2021 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates

29 7 2021 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock

02 7 2021 15:01:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

29 6 2021 20:08:30 提供 Nasdaq GlobeNewswire